Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease

Hyperphosphatemia is a risk factor for ectopic calcification and coronary artery diseases in end stage renal diseases (ESRD). The aim of this study was to assess the effect of low-dose nicotinic acid on hyperphosphatemia in patients with ESRD. This randomized, double-blind clinical trial was done on...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of nephrology 2016-07, Vol.26 (4), p.239-243
Main Authors: Zahed, N, Zamanifar, N, Nikbakht, H
Format: Article
Language:English
Subjects:
Care and treatment
Chronic kidney failure
Dosage and administration
Niacin
Original
Phosphorus imbalance
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperphosphatemia is a risk factor for ectopic calcification and coronary artery diseases in end stage renal diseases (ESRD). The aim of this study was to assess the effect of low-dose nicotinic acid on hyperphosphatemia in patients with ESRD. This randomized, double-blind clinical trial was done on 70 ESRD patients with serum phosphoure ≥5.5 mg/dl. Patients were randomly divided into two equal groups (n = 35) and the intervention group received niacin 25 mg/day as the initial dose. After 4 weeks, in patients who did not respond to treatment, niacin dose was increased up to 50 mg/dl. At the end of week 8, in case there was no treatment effect, the dose was raised to 100 mg/day. The appropriate response to treatment was defined as serum phosphorous level reductions
ISSN:0971-4065
1998-3662
DOI:10.4103/0971-4065.161020